| __timestamp | Merus N.V. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 2652041 |
| Thursday, January 1, 2015 | 839656 | 2361587 |
| Friday, January 1, 2016 | 4478145 | 4472869 |
| Sunday, January 1, 2017 | 16432324 | 5030957 |
| Monday, January 1, 2018 | 11890871 | 4988941 |
| Tuesday, January 1, 2019 | 34110000 | 5196412 |
| Wednesday, January 1, 2020 | 35781000 | 6652774 |
| Friday, January 1, 2021 | 40896000 | 18418247 |
| Saturday, January 1, 2022 | 52200000 | 24827066 |
| Sunday, January 1, 2023 | 59836000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding financial strategies is crucial. Over the past decade, Opthea Limited and Merus N.V. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merus N.V. increased its SG&A spending by over 1,450%, peaking in 2023. In contrast, Opthea Limited's expenses grew by approximately 1,480% during the same period, with a notable surge in 2022. This trend highlights Opthea's aggressive investment in administrative capabilities, potentially signaling a strategic pivot. Interestingly, 2024 data for Merus N.V. is missing, leaving room for speculation on its future financial maneuvers. As these companies navigate the biotech sector, their SG&A spending patterns offer insights into their operational priorities and market strategies.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated